Collins v. Ethicon, Inc. et al, No. 2:2012cv00931 - Document 120 (S.D.W. Va. 2016)

Court Description: MEMORANDUM OPINION AND ORDER (Daubert Motion re: Shelby Thames, Ph.D.) The court DENIES in part, GRANTS in part, and RESERVES in part the Motion filed in MDL 2327 by Certain Plaintiffs in Wave 1 Cases to Exclude the Opinions and Testimony of Shelby Thames, as more fully set forth herein. Signed by Judge Joseph R. Goodwin on 9/2/2016. (cc: attys; any unrepresented party) (REF: MDL 2327; Cases Listed on Exhibit) (kll)
Download PDF
Collins v. Ethicon, Inc. et al Doc. 120 IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA CHARLESTON DIVISION IN RE: ETHICON, INC. PELVIC REPAIR SYSTEMS PRODUCT LIABILITY LITIGATION MDL No. 2327 ______________________________________________________________________________ THIS DOCUMENT RELATES TO: Cases Identified in the Exhibit Attached Hereto MEMORANDUM OPINION AND ORDER (Daubert Motion re: Shelby Thames, Ph.D.) Pending before the court is the Motion to Exclude the Opinions and Testimony of Shelby Thames [ECF No. 2039] filed by the plaintiffs. The Motion is now ripe for consideration because briefing is complete. I. Background This case resides in one of seven MDLs assigned to me by the Judicial Panel on Multidistrict Litigation concerning the use of transvaginal surgical mesh to treat pelvic organ prolapse (“POP”) and stress urinary incontinence (“SUI”). In the seven MDLs, there are more than 75,000 cases currently pending, approximately 30,000 of which are in this MDL, which involves defendants Johnson & Johnson and Ethicon, Inc. (collectively “Ethicon”), among others. In this MDL, the court’s tasks include “resolv[ing] pretrial issues in a timely and expeditious manner” and “resolv[ing] important evidentiary disputes.” Barbara J. Rothstein & Catherine R. Borden, Fed. Judicial Ctr., Managing Multidistrict Dockets.Justia.com Litigation in Products Liability Cases 3 (2011). To handle motions to exclude or to limit expert testimony pursuant to Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), the court developed a specific procedure. In Pretrial Order (“PTO”) No. 217, the court instructed the parties to file only one Daubert motion per challenged expert, to file each motion in the main MDL—as opposed to the individual member cases—and to identify which cases would be affected by the motion. PTO No. 217, at 4.1 II. Preliminary Matters Before plunging into the heart of the Motion, a few preliminary matters need to be addressed. I am compelled to comment on the parties’ misuse of my previous Daubert rulings on several of the experts offered in this case. See generally Sanchez v. Bos. Sci. Corp., No. 2:12-cv-05762, 2014 WL 4851989 (S.D. W. Va. Sept. 29, 2014); Tyree v. Bos. Sci. Corp., 54 F. Supp. 3d 501 (S.D. W. Va. 2014); Eghnayem v. Bos. Sci. Corp., 57 F. Supp. 3d 658 (S.D. W. Va. 2014). The parties have, for the most part, structured their Daubert arguments as a response to these prior rulings, rather than an autonomous challenge to or defense of expert testimony based on its reliability and relevance. In other words, the parties have comparatively examined expert testimony and have largely overlooked Daubert’s core considerations for assessing expert testimony. Although I recognize the tendency of my prior evidentiary determinations The plaintiffs identified the Wave 1 cases affected by this Motion in their attached Exhibit A [ECF No. 2039-1], which the court has attached to this Memorandum Opinion and Order. At the time of transfer or remand, the parties will be required to designate relevant pleadings from MDL 2327, including the motion, supporting memorandum, response, reply, and exhibits referenced herein. 1 2 to influence subsequent motions practice, counsels’ expectations that I align with these previous rulings when faced with a different record are misplaced, especially when an expert has issued new reports and given additional deposition testimony. Mindful of my role as gatekeeper for the admission of expert testimony, as well as my duty to “respect[ ] the individuality” of each MDL case, see In re Phenylpropanolamine Prods. Liab. Litig., 460 F.3d 1217, 1231 (9th Cir. 2006), I refuse to credit Daubert arguments that simply react to the court’s rulings in Sanchez and its progeny. Indeed, I feel bound by these earlier cases only to the extent that the expert testimony and Daubert objections presented to the court then are identical to those presented now. Otherwise, I assess the parties’ Daubert arguments anew. That is, in light of the particular expert testimony and objections currently before me, I assess “whether the reasoning or methodology underlying the testimony is scientifically valid” and “whether that reasoning or methodology properly can be applied to the facts in issue.” Daubert, 509 U.S. at 592–93. Any departure from Sanchez, Eghnayem, or Tyree does not constitute a “reversal” of these decisions and is instead the expected result of the parties’ submission of updated expert reports and new objections to the expert testimony contained therein. Finally, I have attempted to resolve all possible disputes before transfer or remand, including those related to the admissibility of expert testimony pursuant to Daubert. Nevertheless, in some instances I face Daubert challenges where my interest in accuracy counsels reserving ruling until the reliability of the expert testimony may be evaluated at trial. At trial, the expert testimony will be tested by 3 precise questions asked and answered. The alternative of live Daubert hearings is impossible before transfer or remand because of the numerosity of such motions in these seven related MDLs. As these MDLs have grown and the expert testimony has multiplied, I have become convinced that the critical gatekeeping function permitting or denying expert testimony on decisive issues in these cases is best made with a live expert on the witness stand subject to vigorous examination. In the course of examining a multitude of these very similar cases involving the same fields of expertise, I have faced irreconcilably divergent expert testimony offered by witnesses with impeccable credentials, suggesting, to me, an unreasonable risk of unreliability. The danger—and to my jaded eye, the near certainty—of the admission of “junk science” looms large in this mass litigation. The parties regularly present out-of-context statements, after-the-fact rationalizations of expert testimony, and incomplete deposition transcripts. This, combined with the above-described practice of recycling expert testimony, objections, and the court’s prior rulings, creates the perfect storm of obfuscation. Where further clarity is necessary, I believe it can only be achieved through live witness testimony— not briefing—I will therefore reserve ruling until expert testimony can be evaluated firsthand. III. Legal Standard By now, the parties should be intimately familiar with Rule 702 of the Federal Rules of Evidence and Daubert, so the court will not linger for long on these standards. 4 Expert testimony is admissible if the expert is qualified and if his or her expert testimony is reliable and relevant. Fed. R. Evid. 702; see also Daubert, 509 U.S. at 597. An expert may be qualified to offer expert testimony based on his or her “knowledge, skill, experience, training, or education.” Fed. R. Evid. 702. Reliability may turn on the consideration of several factors: (1) whether a theory or technique can be or has been tested; (2) whether it has been subjected to peer review and publication; (3) whether a technique has a high known or potential rate of error and whether there are standards controlling its operation; and (4) whether the theory or technique enjoys general acceptance within a relevant scientific community. Cooper v. Smith & Nephew, Inc., 259 F.3d 194, 199 (4th Cir. 2001) (citing Daubert, 509 U.S. at 592–94). But these factors are neither necessary to nor determinative of reliability in all cases; the inquiry is flexible and puts “principles and methodology” above conclusions and outcomes. Daubert, 509 U.S. at 595; see also Kumho Tire Co. v. Carmichael, 525 U.S. 137, 141, 150 (1999). Finally, and simply, relevance turns on whether the expert testimony relates to any issues in the case. See, e.g., Daubert, 509 U.S. at 591–92 (discussing relevance and helpfulness). At bottom, the court has broad discretion to determine whether expert testimony should be admitted or excluded. Cooper, 259 F.3d at 200. IV. Discussion Dr. Thames is a polymer chemist with a Ph.D. in organic chemistry. In 1969, Dr. Thames founded the Department of Polymer Science at the University of Southern Mississippi, and he has served as the Dean of the College of Science. Dr. 5 Thames’s has researched and designed polymers for various uses. a. Properties First, the plaintiffs challenge multiple statements made in Dr. Thames’s expert report that are related to degradation and the support—or lack thereof—found in Ethicon’s seven-year dog study. The plaintiffs argue that this testimony is unreliable because Dr. Thames contradicts himself and misstates the study’s findings. I do not find any of Dr. Thames’s supposed self-contradictions to warrant exclusion. Nor is Dr. Thames’s testimony unreliably contradictory to the extent it uses the dog study to support his opinion that Prolene “does not undergo meaningful or harmful degradation in vivo.” Thames Report 6 [ECF No. 2039-3]. I do agree, however, with the plaintiffs’ argument that Dr. Thames has occasionally misstated the dog study’s specific findings as to molecular weight. Specifically, although the study reported no significant difference in molecular weights, Dr. Thames reports the study as finding no molecular weight change. See, e.g., Thames Report 9. Insofar as Dr. Thames’s testimony mischaracterizes the dog study’s results on molecular weight change, it is EXCLUDED and the plaintiffs’ Motion on this point is GRANTED. Second, the plaintiffs challenge the reliability of Dr. Thames’s opinion that the data collected from the seven-year dog study “validates toughness improvement after initial implantation.” Mem. 5 [ECF No. 2042] (citing Thames Report 9). The plaintiffs disagree with the manner in which Dr. Thames has defined and measured “toughness.” But the plaintiffs provide no support for their differing conception of the term or how it is most appropriately measured. Additionally, a review of Dr. Thames’s 6 expert report and Ethicon’s Response shows that he used a systematic method to plot data collected in the dog study on strength and elongation that could reasonably be said to relate to toughness. Accordingly, the plaintiffs’ Motion on this matter is DENIED. Third, the plaintiffs challenge Dr. Thames’s opinions on translucent flakes detected on Prolene explants and the presence of extrusion lines. These opinions, however, are apparently contained in Dr. Thames’s case-specific expert report regarding a particular Wave 1 plaintiff. As such, these objections are not appropriately addressed in the instant Daubert motion, which was filed in the main MDL and should challenge general causation opinions only. The plaintiffs’ Motion on this matter is DENIED. Further, the plaintiffs’ Motion, insofar as it relates to the cleaning protocol employed by Dr. Thames in his plaintiff-specific examination of mesh, is similarly DENIED. V. Recurring Issues Many of the Daubert motions filed in this MDL raise the same or similar objections. One particular issue has been a staple in this litigation, so I find it best to discuss it in connection with every expert. A number of the Daubert motions seek to exclude FDA testimony and other regulatory or industry standards testimony. To the extent this Motion raises these issues it is GRANTED in part and RESERVED in part as described below. I have repeatedly excluded evidence regarding the FDA’s section 510(k) 7 clearance process in these MDLs, and will continue to do so in these case, a position that has been affirmed by the Fourth Circuit. In re C. R. Bard, Inc., 81 F.3d 913, 921–23 (4th Cir. 2016) (upholding the determination that the probative value of evidence related to section 510(k) was substantially outweighed by its possible prejudicial impact under Rule 403). Because the section 510(k) clearance process does not speak directly to safety and efficacy, it is of negligible probative value. See In re C. R. Bard, 81 F.3d at 920 (“[T]he clear weight of persuasive and controlling authority favors a finding that the 510(k) procedure is of little or no evidentiary value.”). Delving into complex and lengthy testimony about regulatory compliance could inflate the perceived importance of compliance and lead jurors “to erroneously conclude that regulatory compliance proved safety.” Id. at 922. Accordingly, expert testimony related to the section 510(k) process, including subsequent enforcement actions and discussion of the information Ethicon did or did not submit in its section 510(k) application, is EXCLUDED. For the same reasons, opinions about Ethicon’s compliance with or violation of the FDA’s labeling and adverse event reporting regulations are EXCLUDED. In addition to representing inappropriate legal conclusions, such testimony is not helpful to the jury in determining the facts at issue in these cases and runs the risk of misleading the jury and confusing the issues. Insofar as this Motion challenges the FDA-related testimony discussed here, the Motion is GRANTED. A number of experts also seek to opine on Ethicon’s compliance with design control and risk management standards. Some of this testimony involves the FDA’s 8 quality systems regulations, and some—likely in an attempt to sidestep my anticipated prohibition on FDA testimony—involve foreign regulations and international standards. I find all of this proposed testimony of dubious relevance. Although these standards relate to how a manufacturer should structure and document risk assessment, the standards do not appear to mandate any particular design feature or prescribe the actual balance that must be struck in weighing a product’s risk and utility. Nor is it clear that the European and other international standards discussed had any bearing on the U.S. medical device industry when the device in question was being designed. Nevertheless, because the nuances of products liability law vary by state, I will refrain from issuing a blanket exclusion on design process and control standards testimony, whether rooted in the FDA or otherwise. Each standard must be assessed for its applicability to the safety questions at issue in this litigation, consistent with state law. I am without sufficient information to make these findings at this time. Accordingly, I RESERVE ruling on such matters until a hearing, where the trial judge will have additional context to carefully evaluate the relevance and potential prejudicial impact of specific testimony. Similarly, I doubt the relevance of testimony on the adequacy of Ethicon’s clinical testing and research, physician outreach, or particular product development procedures and assessments otherwise not encompassed by the above discussion. Again, such matters seem to say very little about the state of the product itself (i.e., whether or not it was defective) when it went on the market. But because the scope 9 of relevant testimony may vary according to differences in state products liability law, I RESERVE ruling on such matters until they may be evaluated in proper context at hearing before the trial court before or at trial. Additional—and more broad—matters also warrant mention. While some of these concerns may not apply to this particular expert, these concerns are raised so frequently that they are worth discussing here First, many of the motions seek to exclude state-of-mind and legal-conclusion expert testimony. Throughout these MDLs, the court has prohibited the parties from using experts to usurp the jury’s fact-finding function by allowing testimony of this type, and I do the same here. E.g., In re C. R. Bard, Inc., 948 F. Supp. 2d 589, 611 (S.D. W. Va. 2013); see also, e.g., United States v. McIver, 470 F.3d 550, 562 (4th Cir. 2006) (“[O]pinion testimony that states a legal standard or draws a legal conclusion by applying law to the facts is generally inadmissible.”); In re Rezulin Prods. Liab. Litig., 309 F. Supp. 2d 531, 546 (S.D.N.Y. 2004) (“Inferences about the intent and motive of parties or others lie outside the bounds of expert testimony.”). Additionally, an expert may not offer expert testimony using “legal terms of art,” such as “defective,” “unreasonably dangerous,” or “proximate cause.” See Perez v. Townsend Eng’g Co., 562 F. Supp. 2d 647, 652 (M.D. Pa. 2008). Second, and on a related note, many of the motions seek to prohibit an expert from parroting facts found in corporate documents and the like. I caution the parties against introducing corporate evidence through expert witnesses. Although an expert may testify about his review of internal corporate documents solely for the purpose 10 of explaining the basis for his or her expert opinions—assuming the expert opinions are otherwise admissible—he or she may not offer testimony that is solely a conduit for corporate information. Third, many of the motions also ask the court to require an expert to offer testimony consistent with that expert’s deposition or report or the like. The court will not force an expert to testify one way or another. To the extent an expert offers inconsistent testimony, the matter is more appropriately handled via crossexamination or impeachment as appropriate and as provided by the Federal Rules of Evidence. Fourth, in these Daubert motions, the parties have addressed tertiary evidentiary matters like whether certain statements should be excluded as hearsay. The court will not exclude an expert simply because a statement he or she discussed may constitute hearsay. Cf. Daubert, 509 U.S. at 595. Hearsay objections are more appropriately raised at trial. Finally, in some of the Daubert motions, without identifying the specific expert testimony to be excluded, the parties ask the court to prevent experts from offering other expert testimony that the moving party claims the expert is not qualified to offer. I decline to make speculative or advisory rulings. I decline to exclude testimony where the party seeking exclusion does not provide specific content or context. VI. Conclusion The court DENIES in part, GRANTS in part, and RESERVES in part the Motion to Exclude the Opinions and Testimony of Shelby Thames [ECF No. 2039]. 11 The court DIRECTS the Clerk to file a copy of this Memorandum Opinion and Order in 2:12-md-2327 and in the Ethicon Wave 1 cases identified in the Exhibit attached hereto. ENTER: 12 September 2, 2016 Exhibit A Exhibit A - Thames Case Identification 2:11 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 Case No. cv 00809 cv 00256 cv 00258 cv 00261 cv 00265 cv 00276 cv 00277 cv 00279 cv 00286 cv 00322 cv 00335 cv 00337 cv 00341 cv 00344 cv 00347 cv 00351 cv 00352 cv 00358 cv 00368 cv 00369 cv 00376 cv 00378 cv 00379 cv 00380 cv 00381 cv 00387 cv 00389 cv 00397 cv 00401 cv 00423 cv 00443 cv 00455 cv 00468 cv 00469 cv 00470 cv 00476 cv 00481 cv 00483 cv 00485 cv 00486 cv 00489 cv 00490 cv 00491 cv 00493 Case Style Wilma Johnson v. Ethicon, et al. Amy and Brent Holland v. Ethicon, et al. Carrie Smith v. Ethicon, et al. Mary F. Cone v. Ethicon, et al. Doris Chappell Jackson v. Ethicon, et al. Cathy and John Warlick v. Ethicon, et al. Joy and Kevin Essman v. Ethicon, et al. Susan Thaman v. Ethicon, et al. Quillan R. and Thomas W. Garnett v. Ethicon, et al. Linda B. Ryan v. Ethicon, et al. Sandra Wolfe v. Ethicon, et al. Kathleen Wolfe v. Ethicon, et al. Helen M. Brown and Robert E. Ruttkay v. Ethicon, et al. Rose and Jesus Gomez v. Ethicon, et al. Deborah and Felipe Lozano v. Ethicon, et al. Kathy Barton v. Ethicon, et al. Charlotte Hargrove v. Ethicon, et al. Amanda and Raymond Deleon v. Ethicon, et al. Sharon and Michael Boggs v. Ethicon, et al. Dawna Hankins v. Ethicon, et al. Charlene Logan Taylor v. Ethicon, et al. Tina and Kenneth Morrow v. Ethicon, et al. Teri Key and Johnny Shively v. Ethicon, et al. Terrie S. and Ralph R. Gregory v. Ethicon, et al. Susan C. and Leonard Hayes v. Ethicon, et al. Maru LuEllen and Thomas Lawrence Kilday v. Ethicon, et al. Janice Renee Swaney v. Ethicon, et al. Deborah A. Smith v. Ethicon, et al. Carol Jean Dimock v. Ethicon, et al. Pamela Free v. Ethicon, et al. Holy and Jason Jones v. Ethicon, et al. Pamela Gray Wheeler and Stan Wheeler v. Ethicon, et al. Amelia R. and Ernest B. Gonzales v. Ethicon, et al. Patricia Tyler v. Ethicon, et al. Mary Jane and Daniel Olson v. Ethicon, et al. Harriet Beach v. Ethicon, et al. Miranda Patterson v. Ethicon, et al. Carey Beth and David Cole v. Ethicon, et al. Danni Laffoon v. Ethicon, et al. Karen and Joel Forester v. Ethicon, et al. Melissa and Charles Clayton v. Ethicon, et al. Shirley and William Freeman v. Ethicon, et al. Gwendolyn T. Young v. Ethicon, et al. Nancy and Daniel Hooper v. Ethicon, et al. Page 1 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 Case No. cv 00494 cv 00495 cv 00496 cv 00497 cv 00498 cv 00499 cv 00500 cv 00501 cv 00504 cv 00505 cv 00506 cv 00510 cv 00511 cv 00516 cv 00517 cv 00539 cv 00540 cv 00547 cv 00548 cv 00554 cv 00555 cv 00567 cv 00571 cv 00591 cv 00594 cv 00595 cv 00601 cv 00609 cv 00651 cv 00652 cv 00654 cv 00657 cv 00663 cv 00666 cv 00669 cv 00679 cv 00683 cv 00736 cv 00737 cv 00738 cv 00746 cv 00747 cv 00748 cv 00749 Case Style Penelope Ann Link and Dan Richard Saurino v. Ethicon, et al. Andrea Carol and Mark Thomas Chandlee v. Ethicon, et al. Sonya M. and James R. Moreland v. Ethicon, et al. Dina Sanders Bennett v. Ethicon, et al. Myndal Johnson v. Ethicon, et al. Kimberly Thomas v. Ethicon, et al. Krystal and Gregory Teasley v. Ethicon, et al. Jennifer and David Sikes v. Ethicon, et al. Donna T. and James W. Pilgreen v. Ethicon, et al. Mary and Kenneth Thurston v. Ethicon, et al. Martha and Stuart Newman v. Ethicon, et al. Charlene Miracle v. Ethicon, et al. Nancy Williams v. Ethicon, et al. Patricia Conti v. Ethicon, et al. Joann Lehman v. Ethicon, et al. Ann Louise Ruppel and Robert Dean Fuller v. Ethicon, et al. Nancy and Kenneth Feidler v. Ethicon, et al. Brenda and James Riddell v. Ethicon, et al. Rhoda Schachtman v. Ethicon, et al. Sharon and Gardner Carpenter v. Ethicon, et al. Carolyn Sue Doyle v. Ethicon, et al. Noemi and Cesar Padilla v. Ethicon, et al. Mary Catherine Wise v. Ethicon, et al. Beverly Kivel v. Ethicon, et al. Frances Ann and Herman Cortez v. Ethicon, et al. Mary and Thomas Hendrix v. Ethicon, et al. Deanna Jean and Bennie G. Thomas v. Ethicon, et al. Patricia O. Powell v. Ethicon, et al. Robin Bridges v. Ethicon, et al. Maria C. and Mark A. Stone v. Ethicon, et al. Stacy and Kevin Shultis v. Ethicon, et al. Judy G. Williams v. Ethicon, et al. Ana Ruebel v. Ethicon, et al. Donna and Leon Loustaunau v. Ethicon, et al. Teresa and Ricky J. Stout v. Ethicon, et al. Lisa and Henry Stevens v. Ethicon, et al. Louise Grabowski v. Ethicon, et al. Karen and Thomas Daniell v. Ethicon, et al. Beth and Stuart Harter v. Ethicon, et al. Sheri and Gary Scholl v. Ethicon, et al. Margaret Kirkpatrick v. Ethicon, et al. Karyn E. and Douglas E. Drake v. Ethicon, et al. Myra abd Richard Byrd v. Ethicon, et al. Jennifer D. and Willem C.J. Van Rensburg v. Ethicon, et al. Page 2 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 Case No. cv 00751 cv 00755 cv 00756 cv 00757 cv 00759 cv 00760 cv 00761 cv 00762 cv 00765 cv 00766 cv 00767 cv 00768 cv 00769 cv 00772 cv 00773 cv 00779 cv 00783 cv 00784 cv 00786 cv 00787 cv 00799 cv 00800 cv 00806 cv 00807 cv 00811 cv 00821 cv 00828 cv 00829 cv 00830 cv 00842 cv 00846 cv 00848 cv 00854 cv 00856 cv 00859 cv 00860 cv 00861 cv 00863 cv 00864 cv 00867 cv 00873 cv 00875 cv 00876 cv 00878 Case Style Raquel and Ernesto De La Torre v. Ethicon, et al. Cheryl Lankston v. Ethicon, et al. Dee and Michael Woolsey v. Ethicon, et al. Barbara Jean and Keith Bridges v. Ethicon, et al. Diane and Robert Matott v. Ethicon, et al. Lois and Gerald Durham v. Ethicon, et al. Barbara J. and Gary L. Ware v. Ethicon, et al. Janet D. Jones v. Ethicon, et al. Rachel and Dwan Taylor v. Ethicon, et al. Kimberly Garnto v. Ethicon, et al. Rebecca and Charles Oehring v. Ethicon, et al. Sandra and Christian LaBadie v. Ethicon, et al. Kimberly T. Burnham v. Ethicon, et al. Harmony Minniefield v. Ethicon, et al. Tina and Keith Patterson v. Ethicon, et al. Dee and Timothy McBrayer v. Ethicon, et al. Wendy Hagans v. Ethicon, et al. Schultz et al v. Ethicon, Inc. et al Swint et al v. Ethicon, Inc et al Joplin v. Ethicon, Inc et al Quijano v. Ethicon, Inc. et al Morrison et al v. Ethicon, Inc et al Hill et al v. Ethicon, Inc. et al Sweeney et al v. Ethicon, Inc. et al Zoltowski et al v. Johnson & Johnson et al Barr et al v. Ethicon, Inc. et al Nix et al v. Ethicon, Inc. et al Georgilakis et al v. Ethicon, Inc et at Parrilla v. Ethicon, Inc. et al Stubblefield v. Ethicon, Inc. et al Raines et al v. Ethicon, Inc. et al Fisk v. Ethicon, Inc et al Ballard et al v. Ethicon, Inc et al Massicot v. Ethicon, Inc. et al Olmstead v. Ethicon, Inc. et al Pelton v. Ethicon, Inc. et al Smith et al v. Ethicon, Inc. et al Gunter et al v. Ethicon, Inc Nolan v. Ethicon, Inc. et al Rock v. Ethicon et al Walker et al v. Ethicon, Inc. et al Holzerland et al v. Ethicon, Inc. et al Hoy et al v. Ethicon, Inc. et al Fox et al v. Johnson & Johnson, Inc. et al Page 3 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 Case No. cv 00880 cv 00883 cv 00886 cv 00887 cv 00888 cv 00899 cv 00921 cv 00923 cv 00931 cv 00938 cv 00939 cv 00956 cv 00957 cv 00958 cv 00960 cv 00961 cv 00967 cv 00995 cv 00997 cv 01004 cv 01011 cv 01013 cv 01018 cv 01021 cv 01023 cv 01052 cv 01053 cv 01071 cv 01081 cv 01088 cv 01090 cv 01119 cv 01121 cv 01124 cv 01145 cv 01146 cv 01148 cv 01149 cv 01150 cv 01151 cv 01171 cv 01198 cv 01199 cv 01202 Case Style Massey et al v. Ethicon, Inc. et al Wroble et al v. Ethicon, Inc et al Umberger et al v. Ethicon, Inc. et al Kaiser et al v. Johnson & Johnson et al Bruhn et al v. Ethicon, Inc et al Barker et al v. Ethicon, Inc. et al Wilson v. Ethicon, Inc et al Atemnkeng et al v. Ethicon, Inc. et al Collins v. Ethicon, Inc. et al Kriz et al v. Ethicon, Inc. et al Reyes et al v. Ethicon, Inc. et al Justus v. Ethicon, Inc. et al Funderburke v. Ethicon, Inc. et al White et al v. Ethicon, Inc. et al Amsden et al v. Ethicon, Inc. et al Greene v. Ethicon, Inc. et al Shepherd v. Ethicon, Inc. et al Blake et al v. Ethicon, Inc. et al Springer et al v. Ethicon, Inc. et al Frye v. Ethicon, Inc. et al Hankins et al v. Ethicon, Inc. et al Lee et al v. Ethicon, Inc. et al Gwinn et al v. Ethicon, Inc. et al Ruiz v. Ethicon, Inc. et al Burkhart v. Ethicon, Inc. et al Babcock v. Ethicon, Inc. et al Baugher v. Ethicon, Inc. et al Schnering et al v. Ethicon, Inc. et al Dixon v. Ethicon, Inc. et al Wheeler et al v. Ethicon, Inc. et al Wright v. Ethicon, Inc. et al Rhynehart v. Ethicon, Inc. et al Guinn v. Ethicon, Inc. et al Bellito Stanford et al v. Ethicon, Inc. et al Constance Daino v. Ethicon, Inc. et al Monica Freitas v. Ethicon, Inc. et al Denise Sacchetti v. Ethicon, Inc. et al Cindy Smith v. Ethicon, Inc. et al Roberta Warmack v. Ethicon, Inc. et al Laura Waynick v. Ethicon, Inc. et al Patti Ann Phelps v. Ethicon, Inc. et al Stacy Pangborn v. Ethicon, Inc. et al Lisa Thompson v. Ethicon, Inc. et al Diane Kropf v. Ethicon, Inc. et al Page 4 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 2:12 Case No. cv 01203 cv 01206 cv 01215 cv 01216 cv 01225 cv 01262 cv 01267 cv 01273 cv 01274 cv 01275 cv 01277 cv 01278 cv 01279 cv 01283 cv 01284 cv 01285 cv 01286 cv 01293 cv 01294 cv 01299 cv 01304 cv 01305 cv 01311 cv 01318 Case Style Joan Adams v. Ethicon, Inc. et al Jeanie Holmes v. Ethicon, Inc. et al Karen Bollinger v. Ethicon, Inc. et al Christine Wiltgen v. Ethicon, Inc. et al Ida Deanne Evans v. Ethicon, Inc. et al Saundra Landes v. Ethicon, Inc. et al Angela Coleman v. Ethicon, Inc. et al Rebekah Barlett v. Ethicon, Inc. et al Janice Colonna v. Ethicon, Inc. et al Long v. Johnson & Johnson et al Duncan v. Ethicon, Inc et al Nix v. Ethicon, Inc. et al Bertoni et al v. Ethicon, Inc. et al Cyrus v. Ethicon, Inc. et al Floyd v. Ethicon, Inc. et al Simpson et al v. Ethicon, Inc. et al Wilson v. Ethicon, Inc. et al Costello v. Ethicon, Inc. et al Herrera Nevarez v. Ethicon, Inc Destefano Rasten et al v. Ethicon, Inc. et al Irwin et al v. Ethicon, Inc. et al Lager v. Ethicon, Inc. et al Ridgley et al v. Ethicon, Inc. et al Banks v. Johnson & Johnson, Inc. et al Page 5